Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity

出版年份 2019 全文链接

标题

作者

关键词

出版物

Volume 36, Issue 4, Pages 444-457.e7

出版商

Elsevier BV

发表日期

2019-10-03

DOI

10.1016/j.ccell.2019.09.001

Discuss science. Find collaborators. Network.

Join a conversation

Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.

Get Started